AI Article Synopsis
- Immune checkpoint inhibitors can boost the immune system to fight tumors but may lead to complications known as immune-related adverse events (irAEs).
- Hematological irAEs, though uncommon, can result in serious conditions like autoimmune hemolytic anemia, immune thrombocytopenia, and even fatal reactions like hemophagocytic lymphohistiocytosis.
- The text outlines the symptoms of these blood-related irAEs and suggests ways to diagnose and treat them effectively.
Article Abstract
Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs). Hematological irAEs are rarely reported, which mainly represent as mono-lineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even lethal, such as hemophagocytic lymphohistiocytosis. The clinical manifestations of hematological irAEs will be summarized and recommendations of diagnosis and treatment are proposed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817424 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!